🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT07429487
Recruiting Not applicable

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

NCT07429487 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09-15
Last updated
2026-09-15

Condition(s) studied

Breast CancerColorectal CancerOvarian AdenocarcinomaPancreatic CancerGastric Adenocarcinoma

Investigational drug(s) / intervention(s)

APA program

APA program: patient will benefit of an activity monitored by a wtach and an APA program during 3 months

Study summary

A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to compare changes in fatigue at 3 months in patients who have completed adjuvant systemic chemotherapy for cancer and are participating in an APA program.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 18 to 75 years old, 2. Histologically proven non-metastatic adenocarcinoma of breast, colorectal, ovarian, pancreatic, biliary, or gastric origin, 3. Adjuvant chemotherapy completed less than 3 months ago (excluding hormone therapy), 4. PS 0 or 1 according to the World Health Organization (WHO) scale, 5. No recurrence since the end of adjuvant chemotherapy, 6. Patient who has voluntarily agreed to participate in the study and sign the written informed consent form, 7. Patient affiliated with a Social Security scheme. Exclusion Criteria: 1. New cancer treatment planned (excluding hormone therapy), 2. Patient who has received adjuvant immunotherapy, 3. Cardiological contraindication to the program 4. Decompensated or unstable chronic conditions 5. Severe malnutrition 6. Rheumatological unfitness as determined by the oncologist, 7. Chronic respiratory failure requiring long-term O2 therapy 8. Diabetes with plantar ulceration 9. Progressive or chronic non-healing bedsore/wound 10. Recent unhealed fracture 11. Patient participating in another interventional clinical study at the time of signing the informed consent form. 12. Vulnerable persons as defined in Articles L1121-5 to -8

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Antoine Lacassagne Nice France Recruiting

More Centre Antoine Lacassagne trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07429487 on ClinicalTrials.gov ↗ ← All trials in France